Shunting for Idiopathic NPH: Randomized Trial Results
- A major clinical trial,the SELECT trial,has revealed a potential increased risk of serious cardiovascular events - including heart attack,stroke,and cardiovascular death - in adults with obesity and established...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- This finding primarily impacts individuals with both obesity and pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial,the SELECT trial,has revealed a potential increased risk of serious cardiovascular events – including heart attack,stroke,and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk.though, it’s crucial to note that the trial also showed a significant reduction in the development of type 2 diabetes among participants.
| outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Heart Attack, Stroke, Cardiovascular Death) | 6.5 | 4.9 | 1.33 |
| New-Onset Type 2 Diabetes | 15.0 | 25.3 | 0.61 |
Who is Affected? Understanding Patient Risk
This finding primarily impacts individuals with both obesity and pre-existing cardiovascular disease. It dose *not* necessarily mean that semaglutide is unsafe for everyone.Patients without established heart conditions may still benefit from the drug’s weight loss effects,but even in these cases,careful monitoring is essential. The trial specifically included participants with a history of heart attack, stroke, or peripheral artery disease.
It’s important to distinguish between semaglutide (Ozempic, used for type 2 diabetes) and liraglutide (Saxenda, specifically approved for weight loss).While both are GLP-1 receptor agonists, the SELECT trial focused solely on semaglutide. Further research is needed to determine if similar risks exist with other medications in this class.
Why Does This Matter? The Shifting Landscape of Obesity Treatment
Semaglutide has been widely hailed as a breakthrough in obesity treatment, demonstrating remarkable weight loss results. This trial introduces a critical nuance: the benefits must be carefully weighed against potential cardiovascular risks, especially in vulnerable populations. the initial enthusiasm surrounding the drug needs to be tempered with a more cautious and individualized approach to prescribing.
Timeline of Events & Ongoing Research
- August 17, 2023: SELECT trial results publicly released.
- Ongoing: Researchers
Worth a look